Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

Targeting the Synaptic Pathway in Neurodevelopmental and Psychiatric Disorders

Project Overview

Autism spectrum disorders are neurodevelopmental disorders characterized by deficits in social interaction, poor communication, and restricted, stereotyped patterns of behavior. Autism and schizophrenia affect over 1% of the population, and each has strong genetic associations with 60-90% heritability among twins. Recent research identified mutations in a shared genetic pathway in autism and schizophrenia, in genes that function to build synaptic connections between nerve cells, specifically in neurexin cell adhesion proteins and partners linked in a biochemical pathway. Mice with autism-associated mutations in neurexin pathway genes exhibit impaired social interactions and have been developed as single-gene models for exploring and treating autism. In this project, Dr. Craig and her team are studying the fundamental properties of the neurexin synaptic pathway in cell culture and animal models of autism. They are using state of the art biochemical, structural, fluorescence imaging, and behavioral assays in both fly and mouse models based on the human genetics to better understand the subtle differences in brain organization and function that occur in these neuropsychiatric disorders. They have discovered novel regulatory mechanisms of the neurexin pathway and will validate their importance in brain function. A major component of this research will be to test the efficacy of novel therapeutic agents for amelioration of behavioural and cellular phenotypes associated with the devastating consequences of these disorders. The teams hopes that such in-depth molecular studies based on the human genetics will ultimately lead to the most effective therapeutics for autism and schizophrenia.

Principal Investigator

Ann Marie Craig , University of British Columbia

Team Members

Michael Gordon, Brain Research Centre, University of British Columbia

Tim Murphy, University of British Columbia

Richard Brown, Dalhousie University

Partners and Donors

Genome BC

University of British Columbia

Project Ongoing

Targeting the Synaptic Pathway in Neurodevelopmental and Psychiatric Disorders

  • Program Type

    Team grants

  • Area of research

    Neurodevelopment

  • Disease Area

    Other

  • Competition

    2014 MIRI Team Grants

  • Province

    British Columbia

  • Start Date

    2015

  • Total Grant Amount

    $1,387,500

  • Health Canada Contribution

    $693,750

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co